BCL2 and neoplasm: Several studies in prostate tumors have shown that elevated expression of BCL‐2, BCL‐xL, and MCL‐1 is associated with tumor aggressiveness, treatment resistance, and metastatic progression.9, 24 Therefore, targeting the antiapoptotic signaling effectors is an attractive strategy to increase apoptotic response in tumors.